ECSP034570A - Formulacion de una solucion de inhalacion con una sal tiotropio - Google Patents

Formulacion de una solucion de inhalacion con una sal tiotropio

Info

Publication number
ECSP034570A
ECSP034570A EC2003004570A ECSP034570A ECSP034570A EC SP034570 A ECSP034570 A EC SP034570A EC 2003004570 A EC2003004570 A EC 2003004570A EC SP034570 A ECSP034570 A EC SP034570A EC SP034570 A ECSP034570 A EC SP034570A
Authority
EC
Ecuador
Prior art keywords
formulation
tiotropio
salt
inhalation solution
water
Prior art date
Application number
EC2003004570A
Other languages
English (en)
Inventor
Christel Schmelzer
Humke Barbara Niklaus
Petra Barth
Karin Drechsel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP034570A publication Critical patent/ECSP034570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Abstract

La presente invención se refiere a una formulación para inhalación exenta de gases propelentes de bromuro de tiotropio o monohidrato de bromuro de tiotropio, disuelto en agua o en una mezcla de agua y etanol, así como a los aerosoles inhalables exentos de gases propelentes resultantes de ella.
EC2003004570A 2000-10-31 2003-04-28 Formulacion de una solucion de inhalacion con una sal tiotropio ECSP034570A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31

Publications (1)

Publication Number Publication Date
ECSP034570A true ECSP034570A (es) 2003-06-25

Family

ID=7661727

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004570A ECSP034570A (es) 2000-10-31 2003-04-28 Formulacion de una solucion de inhalacion con una sal tiotropio

Country Status (33)

Country Link
EP (1) EP1335729A2 (es)
JP (1) JP4559703B2 (es)
KR (1) KR100983208B1 (es)
CN (1) CN1237970C (es)
AR (1) AR038765A1 (es)
AU (2) AU2002221741B2 (es)
BG (1) BG66425B1 (es)
BR (1) BR0115016A (es)
CA (1) CA2427583C (es)
CZ (1) CZ305033B6 (es)
DE (1) DE10152369A1 (es)
EA (1) EA009068B1 (es)
EC (1) ECSP034570A (es)
EE (1) EE05343B1 (es)
HK (1) HK1060569A1 (es)
HR (1) HRP20030337A2 (es)
HU (1) HUP0301377A3 (es)
IL (2) IL155676A0 (es)
ME (1) ME00242B (es)
MX (1) MXPA03003750A (es)
MY (1) MY132777A (es)
NO (1) NO332524B1 (es)
NZ (1) NZ526024A (es)
PE (1) PE20020518A1 (es)
PL (1) PL361001A1 (es)
SA (1) SA01220503B1 (es)
SK (1) SK288031B6 (es)
TW (1) TWI296934B (es)
UA (1) UA76435C2 (es)
UY (1) UY26991A1 (es)
WO (1) WO2002036591A2 (es)
YU (1) YU33103A (es)
ZA (1) ZA200303045B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295195B2 (en) 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US9539221B2 (en) * 2003-10-09 2017-01-10 Egb Advisors, Llc Method of treating airway diseases with β-adrenergic inverse agonists
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
EP1863476B1 (en) * 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US20070274925A1 (en) * 2006-05-26 2007-11-29 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
TR200907237A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz kombinasyonu
WO2020019952A1 (zh) * 2018-07-26 2020-01-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN111971034A (zh) * 2018-07-26 2020-11-20 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
DE59609627D1 (de) * 1995-06-27 2002-10-10 Boehringer Ingelheim Pharma Neue stabile arzneimittelzubereitung zur erzeugung treibgasfreier aerosole
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

Also Published As

Publication number Publication date
BG107726A (bg) 2004-11-30
SA01220503B1 (ar) 2007-03-10
KR20040010552A (ko) 2004-01-31
MY132777A (en) 2007-10-31
EE05343B1 (et) 2010-10-15
EP1335729A2 (de) 2003-08-20
PE20020518A1 (es) 2002-07-12
CN1237970C (zh) 2006-01-25
EE200300202A (et) 2003-10-15
TWI296934B (en) 2008-05-21
UA76435C2 (en) 2006-08-15
NO20031914D0 (no) 2003-04-29
HUP0301377A2 (hu) 2003-10-28
AU2002221741B2 (en) 2007-04-05
EA200300483A1 (ru) 2003-12-25
SK5262003A3 (en) 2003-10-07
MXPA03003750A (es) 2004-10-15
AU2174102A (en) 2002-05-15
BG66425B1 (bg) 2014-04-30
CZ20031487A3 (cs) 2003-09-17
CZ305033B6 (cs) 2015-04-08
UY26991A1 (es) 2002-06-20
NO332524B1 (no) 2012-10-08
EA009068B1 (ru) 2007-10-26
IL155676A (en) 2012-05-31
KR100983208B1 (ko) 2010-09-20
AR038765A1 (es) 2005-01-26
NZ526024A (en) 2005-10-28
WO2002036591A2 (de) 2002-05-10
CA2427583A1 (en) 2002-05-10
JP4559703B2 (ja) 2010-10-13
DE10152369A1 (de) 2002-05-08
SK288031B6 (sk) 2012-12-03
MEP40708A (en) 2011-02-10
YU33103A (sh) 2006-05-25
WO2002036591A3 (de) 2002-07-25
ME00242B (me) 2011-05-10
JP2004523482A (ja) 2004-08-05
NO20031914L (no) 2003-06-23
ZA200303045B (en) 2004-04-22
IL155676A0 (en) 2003-11-23
BR0115016A (pt) 2005-05-03
CA2427583C (en) 2008-02-12
HK1060569A1 (en) 2004-08-13
CN1473044A (zh) 2004-02-04
HUP0301377A3 (en) 2005-12-28
PL361001A1 (en) 2004-09-20
HRP20030337A2 (en) 2005-04-30

Similar Documents

Publication Publication Date Title
ECSP056029A (es) Formulación para un inhalador con dosis medida que emplea hidrofluoroalcanos como propulsores
ECSP034570A (es) Formulacion de una solucion de inhalacion con una sal tiotropio
UY27740A1 (es) Nuevos compuestos
ATE342053T1 (de) Formulierungen zur inhalation
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
HRP20030276B1 (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
UY30440A1 (es) Nuevos compuestos
SV2006002274A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CY1107825T1 (el) Εισπνεομενα σκευασματα τυπου διαλυματος με αλαστιοτροπιου
BR0012951A (pt) Agonistas de retinóides seletivos
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
EA200401305A1 (ru) Аэрозольная композиция для ингаляции, содержащая соль тиотропия
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
AR063597A1 (es) Nueva sal
BR0107483A (pt) Processo para a preparação de um composto
TR200600987T1 (tr) 7-karboksimetiloksi-3',4',5-trimetoksi flavon-monohidrat, hazırlama metodu ve kullanılması
AR057799A1 (es) Derivados de quinolina, composiciones farmaceuticas y uso como antitumorales
CO4750644A1 (es) Nuevo preparado medicamentoso estable para la produccion de aerosoles exentos de gas propulsor